Pharmacokinetic-Pharmacodynamic Target Attainment Analyses To Support Dose Selection for ME1100, an Arbekacin Inhalation Solution

ME1100 (arbekacin inhalation solution) is an inhaled aminoglycoside that is being developed to treat patients with hospital-acquired and ventilator-associated bacterial pneumonia (HABP and VABP, respectively). Pharmacokinetic-pharmacodynamic (PK-PD) target attainment analyses were undertaken to eval...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Antimicrob Agents Chemother
Autori principali: Bhavnani, Sujata M., Hammel, Jeffrey P., Lakota, Elizabeth A., Safir, M. Courtney, VanScoy, Brian D., Nagira, Yu, Rubino, Christopher M., Sato, Nobuo, Koresawa, Tomokazu, Kondo, Kenichiro, Ambrose, Paul G.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Microbiology 2020
Soggetti:
Pharmacology
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7508573/
https://ncbi.nlm.nih.gov/pubmed/32661000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02367-19
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi